This announcement is a separate document:
Neuren Pharmaceuticals Ltd: Trofinetide accepted for Priority Review by Health Canada
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.